Literature DB >> 22613563

Eukaryotic expression vectors bearing genes encoding cytotoxic proteins for cancer gene therapy.

Elena M Glinka1.   

Abstract

Cancer gene therapy is a promising direction for the treatment of cancer patients. A primary goal of all cancer therapies is to selectively target and kill tumour cells. Such therapies are administered via different approaches, including both viral and non-viral delivery; however, both methods have advantages and disadvantages. Transcriptional targeting enables genes encoding toxic proteins to be expressed directly in cancer cells. Numerous vectors have been created with the purpose of killing cancer cells, and some have successfully suppressed malignant tumours. Data concerning the function of vectors bearing genes that encode cytotoxic proteins under the control of different promoters, including tissue/tumour specific and constitutive promoters, is summarised here. This review focuses on vectors that bear genes encoding diphtheria toxin, Pseudomonas exotoxin A, caspases, gef, streptolysin, and melittin. Data describing the efficacy of such vectors have been summarised. Notably, there are vectors that killed cancer cell lines originating from the same type of cancer with differential efficiency. Thus, there is differential inhibition of cancer cell growth dependent on the cell line. In this review, the constructs employing genes whose expression induces cell death and the efficiency with which they suppress cancer cell growth will be summarised.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22613563     DOI: 10.1016/j.plasmid.2012.05.003

Source DB:  PubMed          Journal:  Plasmid        ISSN: 0147-619X            Impact factor:   3.466


  10 in total

Review 1.  Killing of cancer cells through the use of eukaryotic expression vectors harbouring genes encoding nucleases and ribonuclease inhibitor.

Authors:  Elena M Glinka
Journal:  Tumour Biol       Date:  2015-04-01

Review 2.  Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy.

Authors:  Islam Rady; Imtiaz A Siddiqui; Mohamad Rady; Hasan Mukhtar
Journal:  Cancer Lett       Date:  2017-05-20       Impact factor: 8.679

3.  Construction of the plasmid coding for the expression of the EGFP-M-IL-2(88Arg, 125Ala) fusion protein and the anti-tumor effects exerted by the fusion protein in HeLa-60 cells.

Authors:  Guangcan Shao; Dongmeng Qian; Haitao Wang; Zhiyong Yan; Ming Hu; Tongmei Wang; Bin Wang
Journal:  Oncol Lett       Date:  2015-04-20       Impact factor: 2.967

4.  Investigating Efficacy of Three DNA-Aptamers in Targeted Plasmid Delivery to Human Prostate Cancer Cell Lines.

Authors:  Saeedeh Askarian; Niloofar Khandan Nasab; Seyed Hamid Aghaee-Bakhtiari; Mohammad Hassan Jafari Najaf Abadi; Reza Kazemi Oskuee
Journal:  Mol Biotechnol       Date:  2022-07-14       Impact factor: 2.860

5.  Melittin radiosensitizes esophageal squamous cell carcinoma with induction of apoptosis in vitro and in vivo.

Authors:  Hongcheng Zhu; Xi Yang; Jia Liu; Yangyang Ge; Qin Qin; Jing Lu; Liangliang Zhan; Zheming Liu; Hao Zhang; Xiaochen Chen; Chi Zhang; Liping Xu; Hongyan Cheng; Xinchen Sun
Journal:  Tumour Biol       Date:  2014-05-29

6.  Small Circular DNAs in Human Pathology.

Authors:  Stephany Carolina Barreto; Madhuri Uppalapati; Amitabha Ray
Journal:  Malays J Med Sci       Date:  2014-05

Review 7.  Bacteriophage-derived vectors for targeted cancer gene therapy.

Authors:  Md Zahidul Islam Pranjol; Amin Hajitou
Journal:  Viruses       Date:  2015-01-19       Impact factor: 5.048

8.  Targeted breast cancer therapy by harnessing the inherent blood group antigen immune system.

Authors:  Wei Han; Wei Li; Xiaoying Zhang; Zhonghua Du; Xiaoliang Liu; Xin Zhao; Xue Wen; Guanjun Wang; Ji-Fan Hu; Jiuwei Cui
Journal:  Oncotarget       Date:  2017-02-28

Review 9.  Delivery of cancer therapies by synthetic and bio-inspired nanovectors.

Authors:  Tina Briolay; Tacien Petithomme; Morgane Fouet; Nelly Nguyen-Pham; Christophe Blanquart; Nicolas Boisgerault
Journal:  Mol Cancer       Date:  2021-03-24       Impact factor: 27.401

Review 10.  Plant Ribosome-Inactivating Proteins: Progesses, Challenges and Biotechnological Applications (and a Few Digressions).

Authors:  Maria Serena Fabbrini; Miku Katayama; Ikuhiko Nakase; Riccardo Vago
Journal:  Toxins (Basel)       Date:  2017-10-12       Impact factor: 4.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.